These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38130031)

  • 1. Use of physiologically-based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended-release nifedipine.
    Tan ML; Gao Z; Babiskin A; Kim MJ; Fang L; Zhang L; Zhao L
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):247-256. PubMed ID: 38130031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
    Le Merdy M; Tan ML; Sun D; Ni Z; Lee SC; Babiskin A; Zhao L
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):41-51. PubMed ID: 33064292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Omeprazole Administration on the Pharmacokinetics of Oral Extended-Release Nifedipine in Healthy Subjects.
    Zhao L; Sun D; Tan ML; Xu M; Kinjo M; Feng K; Wang H; Lionberger R
    Clin Pharmacol Ther; 2023 Nov; 114(5):1134-1141. PubMed ID: 37669218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
    Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
    J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria.
    Doki K; Darwich AS; Patel N; Rostami-Hodjegan A
    Eur J Pharm Sci; 2017 Nov; 109():111-120. PubMed ID: 28774813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation.
    Wagner C; Thelen K; Willmann S; Selen A; Dressman JB
    J Pharm Sci; 2013 Sep; 102(9):3205-19. PubMed ID: 23696038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
    Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
    Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling.
    Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
    Eur J Pharm Sci; 2021 Mar; 158():105656. PubMed ID: 33253885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.
    Soons PA; van den Berg G; Danhof M; van Brummelen P; Jansen JB; Lamers CB; Breimer DD
    Eur J Clin Pharmacol; 1992; 42(3):319-24. PubMed ID: 1577051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
    Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH
    Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
    Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
    Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib.
    Zhou D; Chen B; Sharma S; Tang W; Pepin X
    Pharm Res; 2023 Feb; 40(2):375-386. PubMed ID: 35478298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
    Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
    Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the drug-drug interaction potential of treosulfan using a physiologically-based pharmacokinetic modelling approach.
    Schaller S; Martins FS; Balazki P; Böhm S; Baumgart J; Hilger RA; Beelen DW; Hemmelmann C; Ring A
    Br J Clin Pharmacol; 2022 Feb; 88(4):1722-1734. PubMed ID: 34519068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update.
    Wedemeyer RS; Blume H
    Drug Saf; 2014 Apr; 37(4):201-11. PubMed ID: 24550106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
    Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.
    Kollipara S; Ahmed T; Praveen S
    Xenobiotica; 2023 May; 53(5):366-381. PubMed ID: 37609899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.